PRESS RELEASE

STOCKHOLM, 27 NOVEMBER 2026 11:25 CET

RaySearch to showcase thermal ablation technology advancements at RSNA 2026

RaySearch Laboratories AB (publ) will participate in the annual RSNA Meeting in Chicago, Illinois, November 29 - December 2. At booth #4951, visitors can explore RaySearch's latest software solutions in thermal ablation, book product demonstrations, and learn how RaySearch is expanding into interventional and diagnostic radiology to support comprehensive cancer care.

RaySearch's thermal ablation confirmation solution was developed in collaboration with leading cancer centers. By combining deformable image registration and Deep Learning Segmentation (DLS), it empowers clinicians to confidently deliver state-of-the-art ablation treatments through automated and streamlined workflows.

Achieving optimal ablation margins is a key factor in improving local tumor control when opting for thermal ablation as treatment approach. The COVER-ALL randomized, phase 2, superiority trial conducted at The University of Texas MD Anderson Cancer Center (1) compared the ablative margins in patients with liver tumors using our advanced image-guided ablation solution versus the margins from traditional visual assessment. Software-based assessment achieved optimal ablation margins in 84% of cases, and only 4% of patients showed local tumor progression. In the visual assessment group, optimal ablation margins were achieved in only 15% of cases, and 15% of patients showed local tumor progression.

Visitors are welcome to RaySearch's booth to learn the latest about thermal ablation directly from our experts. Visitors will also be able to explore RayWorld, RaySearch's connected approach to comprehensive cancer care, with solutions used in more than 1,200 clinics worldwide. Our solutions can support clinical practice and shape the future of interventional oncology.

- RayStation®*, a cutting-edge treatment planning system (TPS), is known for its unmatched speed, precision, and support for a wide range of therapies.
- RayCare®*, the next-generation oncology information system (OIS) designed to unify and streamline clinical workflows across disciplines, brings automation beyond the treatment plan.
- RayIntelligence® is an oncology analytics system (OAS) that enables cancer clinics to collect, structure and analyze data from the entire clinical ecosystem.

More information about RaySearch's activities at the event is available here.

“RaySearch has long been a leader in radiation oncology, and we are bringing our expertise in advanced software and workflow automation to interventional oncology. By supporting thermal ablation with innovative confirmation technology, we aim to support clinicians in making more informed decisions and ultimately improve patient care," says Johan Löf, founder and CEO of RaySearch. "RSNA 2026 is an excellent opportunity to share our vision for a more connected and comprehensive approach to cancer treatment.”

(1) Odisio B, Albuquerque J, Lin Y et al.
Software-based versus visual assessment of the minimal ablative margin in patients with liver tumours undergoing percutaneous thermal ablation (COVER-ALL): a randomised phase 2 trial

For more information, please contact:
Matt Miley, Head of Marketing, RaySearch Laboratories AB
Tel: +46 (0) 8 510 530 00
marketing@raysearchlabs.com

Carolina Strömlid, Head of Investor Relations, RaySearch Laboratories AB
Tel: +46 (0) 708 807 173
ir@raysearchlabs.com

About RaySearch
RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation®* treatment planning system (TPS) and the oncology information system (OIS) RayCare®*. The most recent additions to the RaySearch product line are RayIntelligence® and RayCommand®**. RayIntelligence is an oncology analytics system (OAS) which enables cancer clinics to collect, structure and analyze data. RayCommand, a treatment control system (TCS), is designed to link the treatment machine and the treatment planning and oncology information systems. RaySearch's software has been sold to over 1,200 clinics in 54 countries. The company was founded in 2000 as a spin-off from the Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003 (STO: RAY B). More information is available at raysearchlabs.com.

Learn more about us on:
LinkedIn
YouTube

**Not available for clinical use or commercial sale in the United States.*
***RaySearch products and functionalities may be under ongoing development and/or subject to regulatory review and may not be cleared or approved in all jurisdictions. Some products or functionalities described may not be available for clinical use or for sale in the United States or Canada.*